Clinical trial
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750
Study timeline
Study start (actual)2024-01-19Date precision: day
Registry last updated2026-03-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Solid Tumorunresolved
Cutaneous Tumorunresolved
Subcutaneous Tumorunresolved
Malignant Solid Tumorunresolved
Solid Tumorunresolved
Metastatic Solid Tumorunresolved
Metastasis to Soft Tissueunresolved
Non Small Cell Lung Cancerunresolved
Cutaneous Squamous Cell Carcinomaunresolved
Interventions
tolododekin alfaDRUG
CemiplimabDRUG · verified · RxNorm: cemiplimab
Sponsors & collaborators
Ankyra Therapeutics, Inclead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06171750 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.